Base de dados : MEDLINE
Pesquisa : D27.505.954 [Categoria DeCS]
Referências encontradas : 14 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2 ir para página        

  1 / 14 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28255362
[Au] Autor:Martinho O; Silva-Oliveira R; Cury FP; Barbosa AM; Granja S; Evangelista AF; Marques F; Miranda-Gonçalves V; Cardoso-Carneiro D; de Paula FE; Zanon M; Scapulatempo-Neto C; Moreira MA; Baltazar F; Longatto-Filho A; Reis RM
[Ad] Endereço:Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal;; ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal;; Molecular Oncology Research Center (CPOM), Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
[Ti] Título:HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.
[So] Source:Theranostics;7(3):717-732, 2017.
[Is] ISSN:1838-7640
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Persistent HPV infection alone is not sufficient for cervical cancer development, which requires additional molecular alterations for tumor progression and metastasis ultimately leading to a lethal disease. In this study, we performed a comprehensive analysis of HER family receptor alterations in cervical adenocarcinoma. We detected overexpression of HER protein, mainly HER2, which was an independent prognostic marker for these patients. By using and approaches, we provided evidence that HER inhibitors, allitinib and lapatinib, were effective in reducing cervical cancer aggressiveness. Furthermore, combination of these drugs with glucose uptake blockers could overcome the putative HIF1-α-mediated resistance to HER-targeted therapies. Thus, we propose that the use of HER inhibitors in association with glycolysis blockers can be a potentially effective treatment option for HER-positive cervical cancer patients.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico
Adenocarcinoma/tratamento farmacológico
Antimetabólitos/uso terapêutico
Antineoplásicos/uso terapêutico
Receptores ErbB/antagonistas & inibidores
Receptores ErbB/análise
Neoplasias do Colo do Útero/diagnóstico
Neoplasias do Colo do Útero/tratamento farmacológico
[Mh] Termos MeSH secundário: Acrilamidas/uso terapêutico
Biomarcadores Tumorais/análise
Biomarcadores Tumorais/antagonistas & inibidores
Testes Diagnósticos de Rotina/métodos
Resistência a Medicamentos Antineoplásicos
Feminino
Glucose/metabolismo
Seres Humanos
Quinazolinas/uso terapêutico
Nanomedicina Teranóstica/métodos
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (AST 1306); 0 (Acrylamides); 0 (Antimetabolites); 0 (Antineoplastic Agents); 0 (Biomarkers, Tumor); 0 (Quinazolines); 0 (Therapeutic Uses); 0VUA21238F (lapatinib); EC 2.7.10.1 (ErbB Receptors); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170304
[St] Status:MEDLINE
[do] DOI:10.7150/thno.17154


  2 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28042321
[Au] Autor:Chen L; Xing Q; Zhai Q; Tahtinen M; Zhou F; Chen L; Xu Y; Qi S; Zhao F
[Ad] Endereço:Department of Burns, First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
[Ti] Título:Pre-vascularization Enhances Therapeutic Effects of Human Mesenchymal Stem Cell Sheets in Full Thickness Skin Wound Repair.
[So] Source:Theranostics;7(1):117-131, 2017.
[Is] ISSN:1838-7640
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Split thickness skin graft (STSG) implantation is one of the standard therapies for full thickness wound repair when full thickness autologous skin grafts (FTG) or skin flap transplants are inapplicable. Combined transplantation of STSG with dermal substitute could enhance its therapeutic effects but the results remain unsatisfactory due to insufficient blood supply at early stages, which causes graft necrosis and fibrosis. Human mesenchymal stem cell (hMSC) sheets are capable of accelerating the wound healing process. We hypothesized that pre-vascularized hMSC sheets would further improve regeneration by providing more versatile angiogenic factors and pre-formed microvessels. In this work, cultured hMSC cell sheets (HCS) and pre-vascularized hMSC cell sheets (PHCS) were implanted in a rat full thickness skin wound model covered with an autologous STSG. Results demonstrated that the HCS and the PHCS implantations significantly reduced skin contraction and improved cosmetic appearance relative to the STSG control group. The PHCS group experienced the least hemorrhage and necrosis, and lowest inflammatory cell infiltration. It also induced the highest neovascularization in early stages, which established a robust blood micro-circulation to support grafts survival and tissue regeneration. Moreover, the PHCS grafts preserved the largest amount of skin appendages, including hair follicles and sebaceous glands, and developed the smallest epidermal thickness. The superior therapeutic effects seen in PHCS groups were attributed to the elevated presence of growth factors and cytokines in the pre-vascularized cell sheet, which exerted a beneficial paracrine signaling during wound repair. Hence, the strategy of combining STSG with PHCS implantation appears to be a promising approach in regenerative treatment of full thickness skin wounds.
[Mh] Termos MeSH primário: Transplante de Células-Tronco Mesenquimais/métodos
Células Mesenquimais Estromais/fisiologia
Neovascularização Fisiológica
Transplante de Pele/métodos
Ferimentos e Lesões/terapia
[Mh] Termos MeSH secundário: Animais
Ratos
Pele/anatomia & histologia
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Therapeutic Uses)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171018
[Lr] Data última revisão:
171018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170103
[St] Status:MEDLINE
[do] DOI:10.7150/thno.17031


  3 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27639241
[Au] Autor:Landgraf TN; Fernandes FF; Peron G; Panunto-Castelo A
[Ad] Endereço:Department of Biochemistry and Immunology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
[Ti] Título:Therapeutic effect of monophosphoryl lipid A administration on Paracoccidioides brasiliensis-infected mice.
[So] Source:Med Mycol;55(3):344-348, 2017 Apr 01.
[Is] ISSN:1460-2709
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The lack of antifungals with low toxicity and short-term therapy for patients with paracoccidioidomycosis (PCM) led us to evaluate adjuvants in immunotherapeutic intervention. We have previously shown complete Freund's adjuvant (CFA) to be therapeutic on experimental PCM. Owing to CFA toxicity, here we tested adjuvants approved for clinical use or in preclinical phase in experimental mouse PCM. Of all, only monophosporyl lipid A (MPLA) demonstrates a beneficial effect, by reducing the fungal burden and increasing the concentrations of IFN-γ and TNF-α, which are immunoprotective in PCM. These results suggest that MPLA might improve intervention in PCM.
[Mh] Termos MeSH primário: Fatores Imunológicos/administração & dosagem
Lipídeo A/análogos & derivados
Paracoccidioidomicose/tratamento farmacológico
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Lipídeo A/administração & dosagem
Masculino
Camundongos Endogâmicos BALB C
Usos Terapêuticos
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Immunologic Factors); 0 (Lipid A); 0 (Therapeutic Uses); MWC0ET1L2P (monophosphoryl lipid A)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171101
[Lr] Data última revisão:
171101
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160918
[St] Status:MEDLINE
[do] DOI:10.1093/mmy/myw074


  4 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:27639693
[Au] Autor:Wang Y; Li Z; Zhou Y; Cao J; Zhang H; Gong H; Zhou J
[Ad] Endereço:Key Laboratory of Animal Parasitology of Ministry of Agriculture, Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, 200241, China.
[Ti] Título:Specific histamine binding activity of a new lipocalin from Hyalomma asiaticum (Ixodidae) and therapeutic effects on allergic asthma in mice.
[So] Source:Parasit Vectors;9(1):506, 2016 Sep 17.
[Is] ISSN:1756-3305
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lipocalin proteins are secreted by tick salivary glands as an important strategy to interfere with the immune response of hosts. A large number of lipocalins are secreted, but the functions of most of these proteins are unclear. Here, we report a new lipocalin protein with particular histamine binding capacity, which was isolated from the salivary glands of the tick Hyalomma asiaticum. METHODS: The full length cDNA of the Ha24 gene was obtained by RACE, and Ha24 gene was expressed in E. coli; after protein purification and mice immunizations, specific Polyclonal antibodies (PcAb) were created in response to the recombinant protein. Reverse transcription PCR (RT-PCR), Quantitative PCR (Q-PCR), indirect immunofluorescence antibody (IFA) assay and western blot were used to detect the existence of native Ha24 in ticks. To confirm the histamine-binding capacity of rHa24, a histamine-binding assay was completed in vitro (ELISA) and in vivo by inhibition of allergic asthma in mice. RESULTS: Ha24 is coded by 681 bases, contains 227 amino acids, and has a molecular weight of 23.3 kDa. Abundant expression in the salivary glands of feeding ticks was confirmed by the identification of native Ha24 in ticks. The results of a histamine binding assay both in vitro and in vivo demonstrated that rHa24 binds specifically with histamine in a dose-dependent manner, and can provide relief from allergic asthma in mice. CONCLUSIONS: Ha24 is a new tick lipocalin with specific histamine binding activity that can provide relief from host inflammation response.
[Mh] Termos MeSH primário: Histamina/metabolismo
Proteínas de Insetos/metabolismo
Ixodidae/química
Lipocalinas/metabolismo
Glândulas Salivares/química
[Mh] Termos MeSH secundário: Animais
Asma/tratamento farmacológico
Clonagem Molecular
DNA Complementar
Modelos Animais de Doenças
Escherichia coli/genética
Escherichia coli/metabolismo
Expressão Gênica
Proteínas de Insetos/isolamento & purificação
Lipocalinas/isolamento & purificação
Camundongos
Ligação Proteica
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (DNA, Complementary); 0 (Insect Proteins); 0 (Lipocalins); 0 (Therapeutic Uses); 820484N8I3 (Histamine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171010
[Lr] Data última revisão:
171010
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160919
[St] Status:MEDLINE
[do] DOI:10.1186/s13071-016-1790-0


  5 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27190186
[Au] Autor:Shepelkova G; Evstifeev V; Majorov K; Bocharova I; Apt A
[Ad] Endereço:Laboratory for Immunogenetics, Central Institute for Tuberculosis, Moscow, Russia.
[Ti] Título:Therapeutic Effect of Recombinant Mutated Interleukin 11 in the Mouse Model of Tuberculosis.
[So] Source:J Infect Dis;214(3):496-501, 2016 Aug 01.
[Is] ISSN:1537-6613
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Earlier we demonstrated that blocking of interleukin 11 (IL-11) by systemic administration of anti-IL-11 antibodies attenuates severity of Mycobacterium tuberculosis infection in mice. The substitution W147A in the IL-11 molecule creates the form of cytokine capable to disrupt gp130/IL11R signaling complex formation, thus serving as a high-affinity specific antagonist of IL-11-mediated signaling. We hypothesized that this mutant form of IL-11 may serve as an effective tool for inhibition of native IL-11 activity in vivo. We established the recombinant W147A mutant form of IL-11 in an optimized Escherichia coli expression system and administered it as the aerosol in the lungs of M. tuberculosis-susceptible I/St mice infected with M. tuberculosis Our results show that this therapeutic approach markedly inhibits tuberculous inflammation in lungs, increases the survival time of infected animals, and decreases expression of key inflammatory factors at the RNA and protein levels. These findings are a step toward clinical evaluation of the anti-IL-11 therapy for tuberculosis.
[Mh] Termos MeSH primário: Fatores Imunológicos/administração & dosagem
Interleucina-11/antagonistas & inibidores
Proteínas Mutantes/administração & dosagem
Proteínas Recombinantes/administração & dosagem
Tuberculose Pulmonar/tratamento farmacológico
[Mh] Termos MeSH secundário: Administração por Inalação
Aerossóis
Substituição de Aminoácidos
Animais
Modelos Animais de Doenças
Feminino
Inflamação/patologia
Pulmão/patologia
Camundongos
Análise de Sobrevida
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Aerosols); 0 (Immunologic Factors); 0 (Interleukin-11); 0 (Mutant Proteins); 0 (Recombinant Proteins); 0 (Therapeutic Uses)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170522
[Lr] Data última revisão:
170522
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:160519
[St] Status:MEDLINE
[do] DOI:10.1093/infdis/jiw176


  6 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26296495
[Au] Autor:Marconato L; Stefanello D; Sabattini S; Comazzi S; Riondato F; Laganga P; Frayssinet P; Pizzoni S; Rouquet N; Aresu L
[Ad] Endereço:Centro Oncologico Veterinario, Sasso Marconi, BO, Italy. Electronic address: marconato@centroncologicovet.it.
[Ti] Título:Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma.
[So] Source:Vaccine;33(39):5080-6, 2015 Sep 22.
[Is] ISSN:1873-2518
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The aim of this non-randomized controlled trial was to compare time to progression (TTP), lymphoma-specific survival (LSS), and safety of an autologous vaccine (consisting of hydroxyapatite ceramic powder and Heat Shock Proteins purified from the dogs' tumors, HSPPCs-HA) plus chemotherapy versus chemotherapy alone in dogs with newly diagnosed, clinically advanced, histologically confirmed, multicentric indolent B-cell lymphoma. The vaccine was prepared from dogs' resected lymph nodes and administered as an intradermal injection. Forty-five client-owned dogs were enrolled: 20 dogs were treated with dose-intense chemotherapy, and 25 received concurrent immunotherapy. Both treatment arms were well tolerated, with no exacerbated toxicity in dogs also receiving the vaccine. TTP was significantly longer for dogs treated with chemo-immunotherapy versus those receiving chemotherapy only (median, 209 versus 85 days, respectively, P=0.015). LSS was not significantly different between groups: dogs treated with chemo-immunotherapy had a median survival of 349 days, and those treated with chemotherapy only had a median survival of 200 days (P=0.173). Among vaccinated dogs, those mounting an immune response had a significantly longer TTP and LSS than those with no detectable response (P=0.012 and P=0.003, respectively). Collectively these results demonstrate that vaccination with HSPPCs-HA may produce clinical benefits with no increased toxicity, thereby providing a strategy for enhancing chemotherapy in dogs with advanced indolent lymphoma.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Vacinas Anticâncer/administração & dosagem
Tratamento Farmacológico/métodos
Imunoterapia/métodos
Linfoma de Células B/veterinária
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/efeitos adversos
Vacinas Anticâncer/efeitos adversos
Cães
Quimioterapia Combinada/métodos
Feminino
Imunoterapia/efeitos adversos
Injeções Intradérmicas
Linfoma de Células B/mortalidade
Linfoma de Células B/terapia
Masculino
Estudos Prospectivos
Análise de Sobrevida
Usos Terapêuticos
Fatores de Tempo
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Cancer Vaccines); 0 (Therapeutic Uses)
[Em] Mês de entrada:1606
[Cu] Atualização por classe:150921
[Lr] Data última revisão:
150921
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150823
[St] Status:MEDLINE


  7 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26000061
[Au] Autor:Doleschel D; Rix A; Arns S; Palmowski K; Gremse F; Merkle R; Salopiata F; Klingmüller U; Jarsch M; Kiessling F; Lederle W
[Ad] Endereço:1. Experimental Molecular Imaging, Medical Faculty, RWTH Aachen University, Aachen, Germany.
[Ti] Título:Erythropoietin improves the accumulation and therapeutic effects of carboplatin by enhancing tumor vascularization and perfusion.
[So] Source:Theranostics;5(8):905-18, 2015.
[Is] ISSN:1838-7640
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:Recombinant human erythropoietin (rhuEpo) is currently under debate for the treatment of chemotherapy-induced anemia due to clinical trials showing adverse effects in Epo-treated patients and the discovery of the erythropoietin-receptor (EpoR) in tumor and endothelial cells. Here, using Epo-Cy5.5 as theranostic near-infrared fluorescent probe we analyzed the effects of rhuEpo as co-medication to carboplatin in non-small-cell-lung-cancer (NSCLC)-xenografts with different tumor cell EpoR-expression (H838 ~8-fold higher than A549). Nude mice bearing subcutaneous A549 and H838 NSCLC-xenografts received either only carboplatin or carboplatin and co-medication of rhuEpo in two different doses. Tumor sizes and relative blood volumes (rBV) were longitudinally measured by 3D-contrast-enhanced ultrasound (3D-US). Tumoral EpoR-levels were determined by combined fluorescence molecular tomography (FMT)/ micro computed tomography (µCT) hybrid imaging. We found that rhuEpo predominantly acted on the tumor endothelium. In both xenografts, rhuEpo co-medication significantly increased vessel densities, diameters and the amount of perfused vessels. Accordingly, rhuEpo induced EpoR-phoshorylation and stimulated proliferation of endothelial cells. However, compared with solely carboplatin-treated tumors, tumor growth was significantly slower in the groups co-medicated with rhuEpo. This is explained by the Epo-mediated vascular remodeling leading to improved drug delivery as obvious by a more than 2-fold higher carboplatin accumulation and significantly enhanced tumor apoptosis. In addition, co-medication of rhuEpo reduced tumor hypoxia and diminished intratumoral EpoR-levels which continuously increased during carboplatin (Cp) -treatment. These findings suggest that co-medication of rhuEpo in well balanced doses can be used to improve the accumulation of anticancer drugs. Doses and indications may be personalized and refined using theranostic EpoR-probes.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Antineoplásicos/farmacocinética
Carboplatina/farmacologia
Carboplatina/farmacocinética
Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico
Eritropoetina/administração & dosagem
Neovascularização Patológica
[Mh] Termos MeSH secundário: Animais
Linhagem Celular Tumoral
Modelos Animais de Doenças
Feminino
Xenoenxertos
Seres Humanos
Camundongos Nus
Perfusão
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Therapeutic Uses); 11096-26-7 (Erythropoietin); BG3F62OND5 (Carboplatin)
[Em] Mês de entrada:1602
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150523
[St] Status:MEDLINE
[do] DOI:10.7150/thno.11304


  8 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21614793
[Au] Autor:Savica V; Calò LA; Santoro D; Monardo P; Mallamace A; Bellinghieri G
[Ad] Endereço:Department of Nephrology, University of Messina, Messina, Italy.
[Ti] Título:Urine therapy through the centuries.
[So] Source:J Nephrol;24 Suppl 17:S123-5, 2011 May-Jun.
[Is] ISSN:1724-6059
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Urine has always interested and attracted the attention of people. It was in fact never considered a waste product of the body but rather as a distilled product selected from the blood and containing useful substances for the care of the body. It was referred to as the "gold of the blood" and "elixir of long life," indicating its therapeutic potential. This paper reports on the practice of urine therapy since its origin attributed to the Indian culture, and briefly reviews its use through the centuries and different cultures and traditions. Records from the Egyptians to Jews, Greeks, Romans and from the Middle Ages and the Renaissance testify to the practice of urine therapy--a practice that continues to be found in more recent times, from the 18th century to the present. Experiences with the practice of urine therapy have even been discussed and shared recently in 2 different conferences: in 1996 in India and in 1999 in Germany, where people from different countries shared and presented their own research on urine therapy.
[Mh] Termos MeSH primário: Usos Terapêuticos
Terapêutica/história
Urina
[Mh] Termos MeSH secundário: Saúde Global
História do Século XV
História do Século XVI
História do Século XVII
História do Século XVIII
História do Século XIX
História do Século XX
História do Século XXI
História Antiga
História Medieval
Seres Humanos
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Therapeutic Uses)
[Em] Mês de entrada:1109
[Cu] Atualização por classe:141120
[Lr] Data última revisão:
141120
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110527
[St] Status:MEDLINE
[do] DOI:10.5301/JN.2011.6463


  9 / 14 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:21510898
[Au] Autor:Lin FP; Anthony S; Polasek TM; Tsafnat G; Doogue MP
[Ad] Endereço:Centre for Health Informatics, The University of New South Wales, Sydney, Australia. f.lin@unsw.edu.au
[Ti] Título:BICEPP: an example-based statistical text mining method for predicting the binary characteristics of drugs.
[So] Source:BMC Bioinformatics;12:112, 2011 Apr 21.
[Is] ISSN:1471-2105
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The identification of drug characteristics is a clinically important task, but it requires much expert knowledge and consumes substantial resources. We have developed a statistical text-mining approach (BInary Characteristics Extractor and biomedical Properties Predictor: BICEPP) to help experts screen drugs that may have important clinical characteristics of interest. RESULTS: BICEPP first retrieves MEDLINE abstracts containing drug names, then selects tokens that best predict the list of drugs which represents the characteristic of interest. Machine learning is then used to classify drugs using a document frequency-based measure. Evaluation experiments were performed to validate BICEPP's performance on 484 characteristics of 857 drugs, identified from the Australian Medicines Handbook (AMH) and the PharmacoKinetic Interaction Screening (PKIS) database. Stratified cross-validations revealed that BICEPP was able to classify drugs into all 20 major therapeutic classes (100%) and 157 (of 197) minor drug classes (80%) with areas under the receiver operating characteristic curve (AUC) > 0.80. Similarly, AUC > 0.80 could be obtained in the classification of 173 (of 238) adverse events (73%), up to 12 (of 15) groups of clinically significant cytochrome P450 enzyme (CYP) inducers or inhibitors (80%), and up to 11 (of 14) groups of narrow therapeutic index drugs (79%). Interestingly, it was observed that the keywords used to describe a drug characteristic were not necessarily the most predictive ones for the classification task. CONCLUSIONS: BICEPP has sufficient classification power to automatically distinguish a wide range of clinical properties of drugs. This may be used in pharmacovigilance applications to assist with rapid screening of large drug databases to identify important characteristics for further evaluation.
[Mh] Termos MeSH primário: Mineração de Dados
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos
Preparações Farmacêuticas/análise
[Mh] Termos MeSH secundário: Bases de Dados Factuais
Interações Medicamentosas
Seres Humanos
Farmacocinética
Usos Terapêuticos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Pharmaceutical Preparations); 0 (Therapeutic Uses)
[Em] Mês de entrada:1108
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110423
[St] Status:MEDLINE
[do] DOI:10.1186/1471-2105-12-112


  10 / 14 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:20153285
[Au] Autor:Willcox ML; Bodeker G
[Ti] Título:The ethics of improving African traditional medical practice: a response.
[So] Source:Acta Trop;115(1-2):163-4, 2010 Jul-Aug.
[Is] ISSN:1873-6254
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Mh] Termos MeSH primário: Pesquisa Biomédica/ética
Medicina Tradicional Africana/efeitos adversos
Medicina Tradicional Africana/métodos
Experimentação Humana Terapêutica/ética
[Mh] Termos MeSH secundário: África
Ética
Seres Humanos
Medicina Tradicional Africana/tendências
Usos Terapêuticos
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Therapeutic Uses)
[Em] Mês de entrada:1008
[Cu] Atualização por classe:100525
[Lr] Data última revisão:
100525
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:100216
[St] Status:MEDLINE
[do] DOI:10.1016/j.actatropica.2010.02.006



página 1 de 2 ir para página        
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde